Risk factors

Liquidia (LQDA) risk factors

Item 1A of every Liquidia Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open LQDA in Gloom →
Liquidia's chart, financials and news, free in your browser.Open LQDA in Gloom →
  • FY2025 10-K risk factors
    55 risks8 new7 dropped24 reworded

    YUTREPIA was FDA-approved in May 2025 and commercialized in June, shifting risk toward launch execution and uncertain demand.

    Filed Mar 05, 2026
  • FY2024 10-K risk factors
    56 risks

    YUTREPIA approval and United Therapeutics patent litigation dominate near-term commercial risk.

    Filed Mar 19, 2025